Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505370 | 0.89 | HPGD (0.45) | DAOCHUKKDM4EGABRPGABRD | |
| SCHEMBL27204646 | 0.74 | DAO (0.44) | DAOPARP1MAPTSNCAADORA3 | |
| SCHEMBL27204779 | 0.70 | CHUK (0.45) | CHUKKDM4EGABRPGABRDIKBKB | |
| SCHEMBL191244 | 0.69 | HPGD (0.46) | DAOKDM4EAURKAALDH1A1HPGD | |
| Iodide SCHEMBL8481287 | 0.68 | HPGD (0.45) | DAOKDM4EAURKAALDH1A1HPGD | |
| SCHEMBL31269454 | 0.68 | DAO (0.47) | DAOCHUKKDM4EGABRPGABRD | |
| Hydrochloric Acid SCHEMBL8478843 | 0.68 | HPGD (0.45) | DAOKDM4EAURKAALDH1A1HPGD | |
| SCHEMBL2464427 | 0.66 | DAO (0.53) | DAOCHUKKDM4EGABRPGABRD | |
| SCHEMBL22509607 | 0.66 | DAO (0.53) | DAOCHUKKDM4EGABRPGABRD | |
| SCHEMBL7494057 | 0.66 | DAO (0.53) | DAOCHUKKDM4EGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932641-B1 | Pyrido[4′,3′:4,5]pyrrolo[3,2-b][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11932641-B1 | Pyrido[4′,3′:4,5]pyrrolo[3,2-b][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11932641-B1 | Pyrido[4′,3′:4,5]pyrrolo[3,2-b][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11858934-B1 | Substituted pyrido[4′,3′:5,6]pyrimido[1,2-a]indoles as CK2 inhibitors | King Faisal University (SA) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858934-B1 | Substituted pyrido[4′,3′:5,6]pyrimido[1,2-a]indoles as CK2 inhibitors | CSNK1A1L, CKS2, CSNK2A3 | DAO 264/4885CHUK 88/4885KDM4E 1302/4885 |
| US-11932641-B1 | Pyrido[4′,3′:4,5]pyrrolo[3,2-b][1,7]naphthyridine compounds as CK2 inhibitors | CKS2, PLK1, CKS1B | DAO 2539/4885CHUK 88/4885KDM4E 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.